Year: 2025
Type: article
Abstract: Preclinical studies of the serotonin 2A (5-HT2A) antagonist deramciclane suggested an anxiolytic profile, which has not been unequivocally established in the clinic. The same receptor profile also indicated that the compound may exhibit antidepressant potential. However, evidence for these effects remains inconclusive. The present study examined the effect of the drug in two preclinical tests with predictive validity for antidepressant activity.
Authors: Trevor R. Norman, Caroline McGrath
Institutions: The University of Melbourne, Austin Hospital
Language: English
Subfield: Pharmacology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4415181990
FWCI:
Cites:
Cited by:
Related to: